Vaping-Associated Lung Injury (EVALI) — Explained Clearly

Introduction Vaping-associated lung injury — often referred to as EVALI (e-cigarette, or vaping, product use–associated lung injury) — emerged as a public health concern after clusters of severe respiratory illness were reported among people who used vaping products. Although regulatory actions and public awareness have reduced some risks, understanding EVALI’s causes, signs, diagnosis, treatment, and prevention remains crucial for clinicians, patients, and the general public. This article breaks down the evidence clearly and concisely so you can recognize symptoms early and take appropriate action.

What is EVALI? EVALI is an acute or subacute lung injury linked temporally to the use of e-cigarettes or vaping products. It is not a single uniform disease but a syndrome with variable clinical presentations, ranging from mild shortness of breath to life-threatening respiratory failure. Although many cases have been associated with products containing tetrahydrocannabinol (THC) and additives like vitamin E acetate, not all instances involve the same exposure, and research on exact mechanisms is ongoing.

Common causes and risk factors

• Contaminants and additives: Vitamin E acetate, used as a diluent in some illicit THC vaping cartridges, was strongly implicated in outbreaks. Other oils, lipids, and adulterants can also provoke lung injury.
• Heated aerosol inhalation: Heating solvents, flavoring agents, or additives can produce toxic byproducts (e.g., aldehydes, reactive carbonyls) that injure the airways and alveoli.
• Product source and composition: Illicit or counterfeit cartridges, informal supply chains, and unregulated modifications increase risk.
• Frequency and depth of use: Heavy, prolonged vaping, deep inhalation, and “cloud chasing” behaviors may increase exposure dose.
• Underlying health conditions: Pre-existing lung disease, immunosuppression, or other comorbidities can worsen outcomes.

Typical signs and symptoms EVALI often presents with a combination of respiratory and systemic symptoms, which can mimic infectious pneumonia:

• Respiratory: Cough, shortness of breath (dyspnea), chest pain.
• Systemic: Fever, chills, fatigue, weight loss.
• Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain — surprisingly common in many cases.
  Symptom onset varies from days to weeks after exposure. Because symptoms overlap with COVID-19 and other pneumonias, careful history and testing are essential.

How EVALI is diagnosed Diagnosis is clinical and relies on a combination of exposure history, imaging, laboratory testing, and exclusion of other causes:

• History: Document recent vaping use, product types (THC vs nicotine), frequency, and source of cartridges.
• Imaging: Chest X-ray or computed tomography (CT) typically shows bilateral infiltrates, ground-glass opacities, or diffuse airspace disease.
• Laboratory workup: Rule out infectious causes (viral, bacterial, fungal) with appropriate testing, including COVID-19 when indicated.
• Bronchoscopy/BAL: Bronchoalveolar lavage may reveal lipid-laden macrophages or inflammatory cells; its role is supportive rather than diagnostic alone.
• Exclusion: Diagnosis of EVALI is often made after excluding alternative diagnoses and correlating clinical/imaging findings with vaping exposure.

Treatment and management Early recognition and appropriate management can significantly improve outcomes:

• Supportive care: Oxygen therapy, fluid management, and monitoring for respiratory compromise.
• Corticosteroids: Many patients respond to systemic steroids, which reduce inflammation; dosing and duration should be individualized and guided by clinical response.
• Antibiotics/antivirals: Often started empirically until infectious etiologies are excluded.
• Mechanical ventilation/ECMO: Required in severe respiratory failure cases; outcomes vary.
• Follow-up: Pulmonary function testing and imaging are recommended to monitor recovery; some patients have persistent impairment.

Prevention and harm reduction

• Avoid unregulated products: Do not use THC vaping cartridges from informal sources or products of unknown origin.
• Know ingredients: Be cautious with products that contain oils or unknown diluents; avoid modifications to cartridges or devices.
• Seek help for cessation: For nicotine dependence, use evidence-based cessation resources (counseling, FDA-approved medications). For cannabis dependence or risky use, engage appropriate support.
• Education: Clinicians should ask patients about vaping habits when respiratory symptoms arise and counsel on risks.

Public health implications and ongoing research EVALI highlighted gaps in regulation, surveillance, and consumer knowledge regarding vaping products. Authorities expanded testing of vaping products and implemented public health campaigns, but gaps remain:

• Long-term effects: Research is ongoing into chronic consequences of vaping-related lung injury.
• Product regulation: Better oversight of e-liquids, additives, and supply chains can reduce harm.
• Biomarkers and mechanisms: Studies aim to identify specific toxicants and pathophysiologic pathways to guide prevention and treatment.

Conclusion Vaping-associated lung injury is a preventable and treatable syndrome when recognized early. Awareness of risk factors, timely diagnosis, and appropriate treatment (including corticosteroids and supportive care) are key. The safest option remains avoiding unregulated vaping products and seeking evidence-based help for nicotine or cannabis dependence. Continued surveillance, research, and regulation are necessary to reduce the risk of future outbreaks.